News

Ideas That Generate Results

According to the new report by RNCOS entitled, “Global Antibody Drug Conjugate Market Outlook 2020”, there have been significant developments in the ADC segment. Some of these developments are the increased use of ADCs for the treatment of hematological malignancies. Recently, Seattle Genetics and Bristol Mayer Squibb have collaborated to evaluate Adcetris and Opdivo combination in two planned Phase 1/2 clinical trials for the treatment of hematological malignancies. Also, a novel antibody-drug conjugate has been developed by researchers at Igenica Biotherapeutics for the treatment of this form of cancer.
 
Similarly, researchers at the Scripps Research institute have developed an immunosuppressive antibody drug conjugate targeting T cell hematological malignancies. Apart from hematological malignancies, ADCs are also finding applications in breast cancer treatment. Two ADCs by the name of MM-302 and anti-B7-H4 ADC are being developed by Merrimack Pharmaceuticals and Roche Genentech respectively, for the treatment of HER-positive breast cancer. Also, Oxis Biotech and MultiCell Immunotherapeutics are developing ADC targeting triple-negative breast cancer.
 
This report is spread in 80 pages and provides an in-depth research and rational analysis of the current status and future prospect of the Antibody Drug Conjugate market. The report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved. The report also provides an insight into the key ADCs that are currently in pipeline. A brief analysis on the types of ADCs is being done on the basis of types of drug used, clinical phases and cancers targeted.
 
Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided. At the end, major players of ADC market have been discussed. A brief business overview of every player has been provided alongwith their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM770.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm